<?xml version="1.0" encoding="utf-8" ?><rss version="2.0" xmlns:News="http://www.bing.com/news/search?q=ratiopharm&amp;setmkt=en-US&amp;FORM=BNFD&amp;format=rss"><channel><title>ratiopharm - BingNews</title><link>http://www.bing.com/news/search?q=ratiopharm&amp;setmkt=en-US&amp;FORM=BNFD&amp;format=rss</link><description>Search results</description><image><url>http://www.bing.com/rsslogo.gif</url><title>ratiopharm</title><link>http://www.bing.com/news/search?q=ratiopharm&amp;setmkt=en-US&amp;FORM=BNFD&amp;format=rss</link></image><copyright>Copyright \xc2\xa9 2026 Microsoft. All rights reserved. These XML results may not be used, reproduced or transmitted in any manner or for any purpose other than rendering Bing results within an RSS aggregator for your personal, non-commercial use. Any other use of these results requires express written permission from Microsoft Corporation. By accessing this web page or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions.</copyright><item><title>Teva / Ratiopharm</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a37a014761c4bc5b281727c1b7d12bd&amp;url=https%3a%2f%2fwww.ft.com%2fcontent%2fd7385c96-329e-11df-bf20-00144feabdc0&amp;c=10404268377849709323&amp;mkt=en-us</link><description>Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. After nine months, the heavyweight fight for Ratiopharm is over. Europe’s second biggest generic medicine ...</description><pubDate>Wed, 17 Mar 2010 17:00:00 GMT</pubDate><News:Source>The Financial Times</News:Source></item><item><title>ratiopharm Ulm picking up guard Jaylen Sims</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a37a014761c4bc5b281727c1b7d12bd&amp;url=https%3a%2f%2fsports.yahoo.com%2farticles%2fratiopharm-ulm-picking-guard-jaylen-084454770.html&amp;c=6207807334011814349&amp;mkt=en-us</link><description>The competitive landscape of the upcoming 2026-27 BKT EuroCup season shifted on Sunday as two prominent clubs finalized major roster moves, with ratiopharm Ulm picking up guard Jaylen Sims and ...</description><pubDate>Mon, 15 Jun 2026 02:08:00 GMT</pubDate><News:Source>Yahoo Sports</News:Source></item><item><title>2025 NBA Draft scouting report: Ben Saraf, G, Ratiopharm Ulm</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a37a014761c4bc5b281727c1b7d12bd&amp;url=https%3a%2f%2fsports.yahoo.com%2fnba%2farticle%2f2025-nba-draft-scouting-report-ben-saraf-g-ratiopharm-ulm-170856027.html&amp;c=10482977711445565628&amp;mkt=en-us</link><description>Summary: Saraf is a crafty lefty playmaker who relies on guile, footwork, and body control. Limited shooting and athleticism could cap his upside, but his positional size and skill could be hard to ...</description><pubDate>Wed, 25 Jun 2025 16:59:00 GMT</pubDate><News:Source>Yahoo! Sports</News:Source></item><item><title>NBA Draft: Ratiopharm Ulm Prospects Continue To Impress</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a37a014761c4bc5b281727c1b7d12bd&amp;url=https%3a%2f%2fwww.si.com%2fnba%2fdraft%2fnewsfeed%2f2025-nba-draft-ben-saraf-noa-essengue-ratiopharm-ulm-prospects-continue-to-impress&amp;c=9913414173398852578&amp;mkt=en-us</link><description>Coming into the beginning of the 2025 NBA Draft cycle, Ben Saraf and Noa Essengue both had potential first-round pick conversations surrounding their names. For Saraf, that was due to an elite ...</description><pubDate>Tue, 01 Oct 2024 17:00:00 GMT</pubDate><News:Source>Sports Illustrated</News:Source></item><item><title>Noa Essengue Continues To Fill Up the Box Score for Ratiopharm Ulm</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a37a014761c4bc5b281727c1b7d12bd&amp;url=https%3a%2f%2fwww.si.com%2fnba%2fdraft%2fnewsfeed%2fnoa-essengue-ratiopharm-ulm-box-score-stats&amp;c=9849461206553703471&amp;mkt=en-us</link><description>Ratiopharm Ulm is in the midst of struggles in EuroCup play but that hasn’t stopped Noa Essengue from filling up the box score. The 17-year-old continues to make a case for being one of the strongest ...</description><pubDate>Mon, 25 Nov 2024 16:00:00 GMT</pubDate><News:Source>Sports Illustrated</News:Source></item><item><title>Ratiopharm fields decisive takeover bids-sources</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a37a014761c4bc5b281727c1b7d12bd&amp;url=https%3a%2f%2fwww.reuters.com%2farticle%2fbusiness%2fhealthcare-pharmaceuticals%2fratiopharm-fields-decisive-takeover-bids-sources-idUSLDE6141YN%2f&amp;c=1831327446790887593&amp;mkt=en-us</link><description>Teva and Nordic consortium Actavis/EQT have bid-sources Pfizer has re-emerged as possible contender-sources Talks with more than one could continue after latest round FRANKFURT, Feb 6 (Reuters) - ...</description><pubDate>Sat, 06 Feb 2010 08:27:00 GMT</pubDate><News:Source>Reuters</News:Source></item><item><title>Ratiopharm Ulm's Noa Essengue Continues to Rise Ahead of 2025 NBA Draft</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a37a014761c4bc5b281727c1b7d12bd&amp;url=https%3a%2f%2fwww.yardbarker.com%2fnba%2farticles%2fratiopharm_ulms_noa_essengue_continues_to_rise_ahead_of_2025_nba_draft%2fs1_17089_42327626&amp;c=14428749480202388874&amp;mkt=en-us</link><description>The 2025 NBA Draft is nearly here, and teams are getting final measurements on international prospects as the combine make-up activities took place recently. In addition to a number of other prospects ...</description><pubDate>Sat, 14 Jun 2025 10:30:00 GMT</pubDate><News:Source>Yardbarker</News:Source></item><item><title>Ratiopharm chief is in for the long haul</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a37a014761c4bc5b281727c1b7d12bd&amp;url=https%3a%2f%2fwww.ft.com%2fcontent%2f7c34cf6e-c18d-11de-b86b-00144feab49a&amp;c=14419119361691330668&amp;mkt=en-us</link><description>Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. When Oliver Windholz became Ratiopharm’s chief executive in April 2008, he knew he had embarked on a tough ...</description><pubDate>Sat, 24 Oct 2009 17:00:00 GMT</pubDate><News:Source>The Financial Times</News:Source></item><item><title>Adolf Merckle, head of Phoenix and Ratiopharm, kills himself</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a37a014761c4bc5b281727c1b7d12bd&amp;url=https%3a%2f%2fpharmatimes.com%2fnews%2fadolf_merckle_head_of_phoenix_and_ratiopharm_kills_himself_985771%2f&amp;c=16354439205532226910&amp;mkt=en-us</link><description>German billionaire Adolf Merckle, whose 120-firm conglomerate includes the drugs wholesaler Phoenix and the generics major Ratiopharm, has committed suicide, weighed down by the battle to keep his ...</description><pubDate>Mon, 05 Jan 2009 16:00:00 GMT</pubDate><News:Source>PharmaTimes</News:Source></item><item><title>Actavis taps ex-Ratiopharm chief as CEO</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a37a014761c4bc5b281727c1b7d12bd&amp;url=https%3a%2f%2fwww.fiercepharma.com%2fpharma%2factavis-taps-ex-ratiopharm-chief-as-ceo&amp;c=1717020219088603611&amp;mkt=en-us</link><description>Iceland's Actavis Group didn't succeed in its bid to buy the German generics maker Ratiopharm, but it has nabbed the company's former chief executive. Actavis has chosen the ex-chief of Ratiopharm, ...</description><pubDate>Wed, 23 Jun 2010 03:29:00 GMT</pubDate><News:Source>FiercePharma</News:Source></item><item><title>Ratiopharm fields decisive takeover bids-sources</title><link>http://www.bing.com/news/apiclick.aspx?ref=FexRss&amp;aid=&amp;tid=6a37a014761c4bc5b281727c1b7d12bd&amp;url=https%3a%2f%2fwww.reuters.com%2farticle%2fbusiness%2fhealthcare-pharmaceuticals%2fratiopharm-fields-decisive-takeover-bids-sources-idUSTRE615158%2f&amp;c=6768924945421231881&amp;mkt=en-us</link><description>FRANKFURT (Reuters) - Generic-drug makers Teva and Actavis, backed by Swedish buyout firm EQT, have placed make-or-break bids for German peer Ratiopharm but drug major Pfizer is expected to also be a ...</description><pubDate>Sat, 06 Feb 2010 08:34:00 GMT</pubDate><News:Source>Reuters</News:Source></item></channel></rss>